ClinicalTrials.gg
CompletedNCT04123613Updated Nov 10, 2026Results posted

Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)

A Phase 2 interventional study of DM199 in Kidney Diseases, sponsored by DiaMedica Therapeutics Inc. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by DiaMedica Therapeutics Inc · Phase 2, Interventional, and Treatment

Updated Nov 10, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 416 studies in Kidney Diseases with a site in United States — 64 open to participants now, 93 under way, 15 of them phase 3. Kidney Diseases · United States.

Enrollment
122nd of 318
84 · median 50
Started
2019
with 21 others
Phase 2
67 of 416
6 open now
Registered
288th of 416
by date

Among the 416 studies in Kidney Diseases with a site in United States, this one is the 122nd largest by enrollment of the 318 interventional ones that give a count, is one of 22 that started in 2019, is one of 67 in phase 2, and was the 288th registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 184 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

64 of the 416 studies in Kidney Diseases with a site in United States are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 130 Kidney Diseases studies recruiting now, 76 (58%) set no upper age limit and 34 (26%) stop at 75 or younger; 26 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 416 studies in Kidney Diseases with a site in United States, or all of them as a file.
02

Study summary

An open-label, Phase II, multi-center study evaluating multiple doses of DM199 in participants with chronic kidney disease.

Read the detailed description

This is an open-label, Phase II, multi-center study evaluating DM199 in approximately 90 Participants in three cohorts.

Cohort I: African Americans with CKD (Stage II or III), hypertension and non-diabetic Cohort II: Participants with IgA nephropathy diagnosis and CKD (Stage II or III) Cohort III: Diabetes Mellitus (Type II) with CKD (Stage II or III) and hypertension

Participants in each cohort will be enrolled in a parallel assignment to one of two doses:

Dose 1: DM199 2.0 µg/kg SC 2x week for 95 days Dose 2: DM199 5.0 µg/kg SC 2x week for 95 days

03

Conditions studied

  • Kidney Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort I

  • African American
  • Hypertension as defined by the American Heart Association for Stage I hypertension where systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥ 80 mmHg or on medication for treatment of hypertension.

Cohort II

  • IgA nephropathy confirmed by medical history with

Cohort III

  • Diabetes Mellitus (Type 2) with hypertension where systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥ 80 mmHg or on medication for treatment of hypertension
  • ≥7% at screening

Both Cohorts

  • Participant is willing and able to provide for study participation
  • Participant male or female ≥ 18 years of age
  • Participant has CKD as defined by using CKD EPI for Stage II 60 to \<90 mL/min/1.73 m2 or Stage III 30 to \<60 mL/min/1.73 m2
  • UACR >150 mg/g and \<5000 mg/g at screening
  • Participant is clinically stable with respect to underlying renal impairment as assessed by the Investigator's medical evaluation

Exclusion criteria

Exclusion Criteria:

  • Participant has positive drug test for drugs of abuse and/or positive alcohol breath test at screening and Day 1
  • Participant has a current diagnosis and/or is taking medication or diet control for diabetes (cohort I and II only)
  • Participant has an A1c > 7% at screening (cohort I and II only)
  • Participant received therapy within last 3 months
  • Participant is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits
  • Participant has a history of significant allergic diathesis such as urticaria, angioedema, or anaphylaxis
  • Participant has been previously diagnosed with kidney disease other than for hypertension, IgA or Diabetes Mellitus (Type II)
  • Participant has hypotension as defined by systolic blood pressure ≤ 90 mmHg and diastolic blood pressure ≤ 60 mmHg at screen
  • ACEi or GLP-1 medication prescribed for and taken by Participant (must not be taking for 5 half-lives prior to study drug administration and for 10 days post study drug administration)
  • Participant has a current or active malignancy ≤ 2 years prior to enrollment except basal cell or squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy and ≥ 6 months have elapsed since the procedure
  • Participant has an active infection at the time of enrollment, and/or a history of acute bacterial, viral, or fungal systemic infections that required systemic treatment with a completed therapy in the last 7 days prior to enrollment
  • Participant has known medical history of alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency)
  • Participant is pregnant or nursing or is planning a pregnancy during the study period
  • Participant is male or female of , is participating in sexual activity that could lead to pregnancy and is unable or unwilling to practice medically effective during the study
  • Participant has received any drug or device within 14 days (or 5 half lives, whichever is longer) prior to study drug administration starting on Day 1
  • Participant has renal artery stenosis as determined at screen with medical history
  • Participant received a kidney transplant
  • Participant does not have adequate venous access for blood sampling
  • Participant has any other medical condition which, in the opinion of the Investigator, will make participation medically unsafe or interfere with the study results
  • Participant has any other clinically significant abnormalities in laboratory test results at screening that would, in the opinion of the Investigator, increase the Participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data
  • Participant has any significant arrhythmia or conduction abnormality, which in the opinion of the Investigators and Medical Monitor may interfere with the safety of the Participant
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    2.0 µg/kg, multiple dose

    n=45 with 15 Participants from cohort 1, 15 from cohort 2, and 15 from cohort 3

    Drug: DM199

  • Experimental
    5.0 µg/kg, multiple dose

    n=45 with 15 Participants from cohort 1, 15 from cohort 2 and 15 from cohort 3

    Drug: DM199

Interventions

  • DrugDM199

    A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug

06

What researchers measure

Primary outcomes

  1. Safety as Assessed by Incidence, Severity and Causality of AEs

    The safety population includes all participants who received at least one dose of the study intervention and were evaluated for safety outcomes. Data are summarized using this population to provide a comprehensive assessment of treatment-related adverse events, tolerability, and overall safety, ensuring consistent interpretation of safety findings across study groups.

    Time frame: From initial dose (Day 1) through Day 104

  2. Estimated Glomerular Filtration Rate (eGFR), Change From Baseline

    Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, and eGFR measurements were obtained at baseline and every two weeks through week 16. This longitudinal assessment allowed for the evaluation of trends, stability, or potential treatment-related effects on kidney function, providing important clinical context for interpreting the study outcomes and the overall renal safety profile of the study population.

    Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, and 16

  3. Urine Albumin to Creatinine Ratio (UACR), Change From Baseline

    Urine albumin-to-creatinine ratio (UACR) was assessed as a measure of urinary albumin excretion and kidney health throughout the 16-week period. UACR was calculated from spot urine samples by dividing the urine albumin concentration by the urine creatinine concentration, providing a standardized assessment that minimizes the impact of urine dilution. Measurements were obtained at predefined study visits to evaluate changes from baseline and to monitor the effects of treatment on albuminuria over time. UACR is a clinically relevant marker of kidney damage and disease progression, with higher values generally indicating greater renal impairment and increased risk of adverse kidney and cardiovascular outcomes. Longitudinal assessment of UACR provided important information regarding treatment response, renal function preservation, and the overall kidney-related effects of the study intervention. Note: UACR values are reported in g/kg, which is equivalent to mg/g.

    Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, and 16

  4. Systolic Blood Pressure, Change From Baseline

    Blood pressure was taken at the timepoints defined in the Schedule of Assessments after the participant had been sitting for at least 5 minutes.

    Time frame: Baseline, Day 4 through Day 95

  5. Diastolic Blood Pressure, Change From Baseline

    Blood pressure was taken at the timepoints defined in the Schedule of Assessments after the participant had been sitting for at least 5 minutes.

    Time frame: Baseline, Day 4 through Day 95

  6. Urine KLK1 Concentration Pre and Post DM199 Administration

    Observed urine concentration of KLK1 throughout the treatment period.

    Time frame: Baseline through Day 104

  7. Plasma KLK1 Concentration Pre and Post DM199 Administration

    Observed KLK1 concentration throughout the treatment period.

    Time frame: Baseline through Day 104

Secondary outcomes

  1. Tumor Necrosis Factor Receptor 1 (TNF-R1) Concentration in Plasma, Change From Baseline

    Tumor Necrosis Factor Receptor 1 (TNF-R1) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.

    Time frame: Baseline, Weeks 4, 8, 12, and 14

  2. C-Reactive Protein (CRP) Concentration in Plasma, Change From Baseline

    C-Reactive Protein (CRP) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.

    Time frame: Baseline, Weeks 4, 8, 12, and 14

  3. Matrix Metalloproteainase-9 (MMP-9) Concentration in Plasma, Change From Baseline

    Matrix Metalloproteainase-9 (MMP-9) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement. Matrix Metalloproteinase-9 (MMP-9) was measured throughout the treatment period as a biomarker of extracellular matrix remodeling, inflammation, and tissue injury. MMP-9 is a member of the matrix metalloproteinase family of enzymes that degrade components of the extracellular matrix and play a critical role in physiological and pathological processes, including wound healing, immune cell migration, vascular remodeling, fibrosis, and inflammatory responses. Elevated MMP-9 levels have been associated with various disease states, including chronic kidney disease, cardiovascular disease, inflammatory disorders, and conditions characterized by tissue damage and remodeling.

    Time frame: Baseline, Weeks 4, 8, 12, and 14

  4. Vascular Endothelial Growth Factor (VEGF) Concentration in Plasma, Change From Baseline

    Vascular Endothelial Growth Factor (VEGF) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.

    Time frame: Baseline, Weeks 4, 8, 12, and 14

  5. Cystatin C Concentration in Plasma, Change From Baseline

    Cystatin C concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.

    Time frame: Baseline, Weeks 4, 8, 12, and 14

  6. Prostaglandin E2 Concentration in Plasma, Change From Baseline

    Prostaglandin E2 concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement. Prostaglandin E2 is a biomarker of inflammatory activity, immune regulation, and physiological processes involved in vascular and renal function. PGE2 is a bioactive lipid mediator derived from arachidonic acid through the cyclooxygenase (COX) pathway and is produced by a variety of cell types in response to inflammatory stimuli, tissue injury, and other physiological signals. PGE2 plays an important role in modulating inflammation, vasodilation, blood flow regulation, immune responses, and maintenance of normal kidney function.

    Time frame: Baseline, Weeks 4, 8, 12, and 14

  7. Prostacyclin Concentration in Plasma, Change From Baseline

    Prostacyclin concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement. Prostacyclin is a biomarker of vascular function, endothelial health, and regulation of platelet activity. Prostacyclin, also known as prostaglandin I2 (PGI2), is a biologically active lipid mediator produced primarily by vascular endothelial cells through the cyclooxygenase pathway. It plays a critical role in maintaining vascular homeostasis by promoting vasodilation, inhibiting platelet aggregation, and helping to regulate blood flow and vascular tone. Prostacyclin is also involved in modulating inflammatory responses and protecting against the development of thrombosis and vascular injury.

    Time frame: Baseline, Weeks 4, 8, 12, and 14

  8. Kidney Injury Molecule-1 (KIM-1) Concentration in Urine, Change From Baseline

    Kidney Injury Molecule-1 (KIM-1) concentration in urine measured over the duration of the treatment period and compared to the baseline concentration measurement.

    Time frame: Baseline, Weeks 4, 8, 12, and 14

  9. Neutrophil Gelatinase-Associated Lipocalin (NGAL) Concentration in Urine, Change From Baseline

    Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine measured over the duration of the treatment period and compared to the baseline concentration measurement.

    Time frame: Baseline, Weeks 4, 8, 12, and 14

07

Results

Posted Nov 10, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Started121213121817
Completed8713101515
Not completed450232

Outcome measures

PrimarySafety as Assessed by Incidence, Severity and Causality of AEs

The safety population includes all participants who received at least one dose of the study intervention and were evaluated for safety outcomes. Data are summarized using this population to provide a comprehensive assessment of treatment-related adverse events, tolerability, and overall safety, ensuring consistent interpretation of safety findings across study groups.

Time frame:
From initial dose (Day 1) through Day 104
Reported as:
Count of participants · Participants
Safety as Assessed by Incidence, Severity and Causality of AEs
ParticipantsCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
TEAE71078610
TEAE: Mild262344
TEAE: Moderate335503
TEAE: Severe210023
TEAE: Related152634
TEAE: Unrelated655236
Serious TEAE212024
TEAE Leading to Study Discontinuation010000
TEAE Leading to Death010000
PrimaryEstimated Glomerular Filtration Rate (eGFR), Change From Baseline

Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, and eGFR measurements were obtained at baseline and every two weeks through week 16. This longitudinal assessment allowed for the evaluation of trends, stability, or potential treatment-related effects on kidney function, providing important clinical context for interpreting the study outcomes and the overall renal safety profile of the study population.

Time frame:
Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, and 16
Reported as:
Mean · mL/min/1.73m^2
Estimated Glomerular Filtration Rate (eGFR), Change From Baseline
mL/min/1.73m^2Cohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Week 20.21 ± 6.971-2.34 ± 6.6282.46 ± 4.1946.73 ± 12.901-3.82 ± 11.488-5.39 ± 15.411
Week 40.82 ± 6.405-1.39 ± 6.3091.95 ± 6.270-1.62 ± 4.3980.37 ± 5.687-2.91 ± 7.405
Week 6-0.51 ± 6.459-0.64 ± 7.0512.43 ± 7.3781.56 ± 4.441-1.48 ± 7.512-0.51 ± 7.922
Week 8-3.05 ± 4.121-3.34 ± 6.4983.98 ± 6.255-2.42 ± 5.812-1.88 ± 6.015-1.44 ± 7.948
Week 100.91 ± 4.302-1.63 ± 8.9662.59 ± 5.0013.35 ± 5.5752.43 ± 6.6682.35 ± 12.282
Week 122.68 ± 10.157-2.81 ± 7.3902.83 ± 8.1140.30 ± 4.1713.94 ± 10.4340.16 ± 5.883
Week 141.20 ± 8.307-1.08 ± 7.5362.82 ± 6.300-2.78 ± 4.1933.03 ± 7.8571.23 ± 5.276
Week 16-1.29 ± 4.771-1.37 ± 7.1173.62 ± 5.9891.22 ± 4.6690.97 ± 8.365-1.09 ± 7.705
PrimaryUrine Albumin to Creatinine Ratio (UACR), Change From Baseline

Urine albumin-to-creatinine ratio (UACR) was assessed as a measure of urinary albumin excretion and kidney health throughout the 16-week period. UACR was calculated from spot urine samples by dividing the urine albumin concentration by the urine creatinine concentration, providing a standardized assessment that minimizes the impact of urine dilution. Measurements were obtained at predefined study visits to evaluate changes from baseline and to monitor the effects of treatment on albuminuria over time. UACR is a clinically relevant marker of kidney damage and disease progression, with higher values generally indicating greater renal impairment and increased risk of adverse kidney and cardiovascular outcomes. Longitudinal assessment of UACR provided important information regarding treatment response, renal function preservation, and the overall kidney-related effects of the study intervention. Note: UACR values are reported in g/kg, which is equivalent to mg/g.

Time frame:
Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, and 16
Reported as:
Mean · g/kg
Urine Albumin to Creatinine Ratio (UACR), Change From Baseline
g/kgCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Week 2-284.70 ± 703.650-27.51 ± 290.362212.32 ± 578.04723.72 ± 287.870-52.93 ± 454.635-122.62 ± 598.592
Week 4-69.58 ± 227.248-64.40 ± 213.027280.03 ± 925.341-117.77 ± 186.531300.85 ± 1231.140-164.76 ± 629.004
Week 6-368.82 ± 710.979-46.39 ± 211.168507.61 ± 1156.36117.37 ± 447.865512.44 ± 1155.188-57.55 ± 585.035
Week 8-121.49 ± 306.68991.61 ± 320.425344.88 ± 1106.9090.43 ± 407.291348.58 ± 1067.792208.26 ± 903.591
Week 10-425.72 ± 723.89920.91 ± 274.051361.47 ± 1115.104-43.38 ± 281.221152.62 ± 636.389-439.69 ± 1416.742
Week 12-340.30 ± 621.339-22.04 ± 220.814472.15 ± 1275.223-121.54 ± 298.325436.20 ± 850.279299.60 ± 1098.347
Week 14-421.26 ± 779.831-152.32 ± 229.611357.03 ± 1143.252-10.61 ± 226.721530.53 ± 1151.726300.85 ± 836.208
Week 16-331.20 ± 853.63341.17 ± 439.579174.37 ± 1171.124-202.90 ± 327.738498.97 ± 1100.81998.40 ± 1002.859
PrimarySystolic Blood Pressure, Change From Baseline

Blood pressure was taken at the timepoints defined in the Schedule of Assessments after the participant had been sitting for at least 5 minutes.

Time frame:
Baseline, Day 4 through Day 95
Reported as:
Mean · mmHg
Systolic Blood Pressure, Change From Baseline
mmHgCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Day 47.5 ± 31.876.3 ± 14.917.2 ± 14.235.8 ± 13.18-1.5 ± 15.500.7 ± 18.80
Week 2 - Day 811.2 ± 33.03-1.0 ± 21.858.5 ± 17.316.5 ± 15.72-4.5 ± 13.06-1.7 ± 13.16
Week 2 - Day 1113.1 ± 43.62-3.1 ± 12.638.2 ± 9.966.1 ± 12.52-1.6 ± 13.52-7.4 ± 13.39
Week 3 - Day 153.7 ± 26.75-1.0 ± 16.314.9 ± 10.961.8 ± 13.64-1.6 ± 14.69-6.3 ± 15.10
Week 3 - Day 18-1.1 ± 27.34-4.2 ± 14.897.8 ± 10.4110.1 ± 22.010.9 ± 15.49-6.2 ± 17.31
Week 4 - Day 22-6.0 ± 22.30-2.4 ± 16.602.0 ± 9.532.2 ± 12.06-5.8 ± 12.361.3 ± 19.35
Week 4 - Day 2512.4 ± 40.12-7.9 ± 12.760.1 ± 9.73-0.8 ± 12.43-0.5 ± 11.35-3.6 ± 14.86
Week 5 - Day 291.4 ± 30.51-0.5 ± 17.261.6 ± 11.980.5 ± 10.35-2.1 ± 14.66-7.5 ± 15.36
Week 5 - Day 3211.2 ± 38.50-5.8 ± 18.29-0.2 ± 9.855.7 ± 16.17-3.6 ± 11.17-0.3 ± 14.24
Week 6 - Day 364.5 ± 33.57-9.1 ± 11.86-0.6 ± 19.152.9 ± 9.22-1.5 ± 14.412.6 ± 13.90
Week 6 - Day 398.7 ± 33.88-6.2 ± 18.81-1.7 ± 12.773.8 ± 13.76-3.5 ± 10.32-3.2 ± 15.14
Week 7 - Day 43-4.0 ± 28.41-2.9 ± 17.91-2.1 ± 13.220.1 ± 12.20-6.3 ± 14.93-5.2 ± 15.16
Week 7 - Day 465.5 ± 39.95-7.8 ± 19.041.0 ± 18.230.6 ± 8.36-2.3 ± 14.324.2 ± 15.86
Week 8 - Day 50-17.5 ± 29.16-6.0 ± 16.163.6 ± 7.811.4 ± 14.45-3.1 ± 15.53-0.4 ± 15.27
Week 8 - Day 53-19.6 ± 33.30-9.7 ± 19.661.4 ± 15.050.1 ± 8.48-10.5 ± 13.30-2.5 ± 19.31
Week 9 - Day 57-5.6 ± 27.77-0.1 ± 20.15-2.2 ± 17.78-0.8 ± 14.05-4.1 ± 18.48-0.5 ± 25.18
Week 9 - Day 60-15.3 ± 26.04-6.0 ± 14.59-0.2 ± 18.537.1 ± 12.95-1.6 ± 23.494.6 ± 22.32
Week 10 - Day 64-14.2 ± 36.95-6.4 ± 18.15-0.2 ± 11.31-3.7 ± 20.51-4.8 ± 13.975.3 ± 19.37
Week 10 - Day 67-10.2 ± 31.66-2.1 ± 26.08-1.1 ± 16.992.6 ± 12.59-2.1 ± 17.410.9 ± 18.54
Week 11 - Day 71-14.9 ± 28.12-1.4 ± 18.511.9 ± 18.590.4 ± 9.40-2.6 ± 18.895.1 ± 21.95
Week 11 - Day 74-17.8 ± 31.60-1.1 ± 15.863.5 ± 20.301.6 ± 10.60-5.4 ± 11.535.2 ± 21.13
Week 12 - Day 78-17.2 ± 27.49-6.1 ± 18.646.8 ± 14.292.9 ± 13.42-4.0 ± 13.97-3.1 ± 18.63
Week 12 - Day 81-11.2 ± 26.74-4.1 ± 18.511.8 ± 18.08-0.7 ± 14.79-6.1 ± 14.071.3 ± 22.37
Week 13 - Day 85-16.8 ± 30.46-9.7 ± 14.90-0.7 ± 15.432.6 ± 8.68-3.9 ± 18.700.8 ± 14.17
Week 13 - Day 88-13.1 ± 32.82-8.3 ± 20.21-1.0 ± 8.431.7 ± 11.55-4.5 ± 17.841.7 ± 18.81
Week 14 - Day 92-17.4 ± 34.44-4.9 ± 13.803.5 ± 13.052.8 ± 10.11-4.5 ± 18.800.4 ± 15.08
Week 14 - Day 95-16.6 ± 34.26-2.4 ± 17.23-1.4 ± 11.770.3 ± 11.65-9.2 ± 11.513.5 ± 16.37
PrimaryDiastolic Blood Pressure, Change From Baseline

Blood pressure was taken at the timepoints defined in the Schedule of Assessments after the participant had been sitting for at least 5 minutes.

Time frame:
Baseline, Day 4 through Day 95
Reported as:
Mean · mmHg
Diastolic Blood Pressure, Change From Baseline
mmHgCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Day 41.5 ± 11.010.6 ± 7.095.8 ± 10.587.5 ± 9.81-4.2 ± 7.940.7 ± 12.97
Week 2 - Day 80.5 ± 16.16-3.7 ± 10.346.4 ± 11.415.3 ± 11.161.9 ± 8.501.1 ± 9.34
Week 2 - Day 114.1 ± 20.160.0 ± 8.404.6 ± 8.857.9 ± 8.280.9 ± 8.08-0.8 ± 7.64
Week 3 - Day 15-3.5 ± 10.31-0.6 ± 11.611.4 ± 11.672.8 ± 11.871.8 ± 7.990.4 ± 10.48
Week 3 - Day 18-10.9 ± 9.27-4.5 ± 13.663.5 ± 11.234.5 ± 12.340.3 ± 7.64-2.8 ± 9.15
Week 4 - Day 22-1.7 ± 8.35-2.1 ± 12.27-0.3 ± 10.443.5 ± 5.99-1.3 ± 8.43-0.4 ± 7.00
Week 4 - Day 25-3.2 ± 15.19-7.4 ± 11.51-1.1 ± 10.96-0.4 ± 7.140.1 ± 6.802.4 ± 10.41
Week 5 - Day 29-3.3 ± 18.26-1.4 ± 8.533.2 ± 12.281.4 ± 11.32-0.6 ± 9.43-0.1 ± 13.85
Week 5 - Day 321.3 ± 19.81-4.2 ± 15.341.1 ± 8.855.8 ± 11.96-0.3 ± 11.270.2 ± 11.55
Week 6 - Day 36-1.9 ± 16.66-5.8 ± 11.520.0 ± 10.153.6 ± 8.962.2 ± 6.471.9 ± 9.93
Week 6 - Day 39-10.0 ± 15.81-2.2 ± 12.71-1.3 ± 9.183.5 ± 9.54-0.8 ± 9.450.3 ± 11.39
Week 7 - Day 43-8.0 ± 10.11-3.3 ± 10.98-1.6 ± 8.133.1 ± 9.330.1 ± 9.14-2.1 ± 11.21
Week 7 - Day 46-6.9 ± 15.70-2.2 ± 10.76-2.4 ± 13.651.8 ± 8.951.6 ± 8.221.9 ± 8.51
Week 8 - Day 50-6.6 ± 21.67-1.6 ± 11.04-0.1 ± 8.03-0.2 ± 9.501.1 ± 7.500.9 ± 7.49
Week 8 - Day 53-14.8 ± 18.19-3.2 ± 13.07-2.8 ± 9.410.4 ± 10.83-2.5 ± 6.64-2.7 ± 10.13
Week 9 - Day 57-6.4 ± 17.12-3.7 ± 9.740.8 ± 13.530.5 ± 9.61-1.5 ± 10.81-1.6 ± 6.60
Week 9 - Day 60-13.1 ± 15.38-4.9 ± 8.541.5 ± 11.286.2 ± 11.040.0 ± 11.673.8 ± 10.91
Week 10 - Day 64-14.4 ± 16.18-4.6 ± 8.26-0.1 ± 8.741.3 ± 16.40-0.8 ± 7.01-0.1 ± 10.94
Week 10 - Day 67-17.2 ± 15.50-2.3 ± 11.941.9 ± 13.794.0 ± 14.100.8 ± 7.761.9 ± 10.96
Week 11 - Day 71-13.6 ± 17.660.7 ± 11.261.5 ± 13.745.3 ± 9.580.5 ± 14.083.5 ± 10.24
Week 11 - Day 74-12.3 ± 17.76-4.0 ± 15.262.7 ± 13.463.1 ± 10.872.7 ± 10.223.2 ± 15.48
Week 12 - Day 78-9.0 ± 19.231.4 ± 11.06-1.3 ± 12.82-1.0 ± 10.26-3.2 ± 5.93-2.7 ± 10.19
Week 12 - Day 81-9.8 ± 16.05-4.4 ± 10.611.2 ± 11.324.2 ± 13.13-1.8 ± 6.661.9 ± 13.10
Week 13 - Day 85-14.1 ± 18.48-4.6 ± 7.28-0.9 ± 11.564.9 ± 10.581.9 ± 14.250.3 ± 10.24
Week 13 - Day 88-13.6 ± 19.10-8.7 ± 10.140.9 ± 8.865.2 ± 12.42-1.0 ± 6.740.4 ± 12.20
Week 14 - Day 92-13.6 ± 16.15-5.4 ± 8.341.0 ± 12.403.3 ± 10.69-5.2 ± 9.09-0.1 ± 9.52
Week 14 - Day 95-10.6 ± 21.17-1.9 ± 10.27-1.8 ± 8.95-4.1 ± 9.56-0.9 ± 5.082.1 ± 13.09
PrimaryUrine KLK1 Concentration Pre and Post DM199 Administration

Observed urine concentration of KLK1 throughout the treatment period.

Time frame:
Baseline through Day 104
Reported as:
Mean · ng/mL
Urine KLK1 Concentration Pre and Post DM199 Administration
ng/mLCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort I: 2 ug/kg DM199ICohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Baseline37.51 ± 50.02417.90 ± 16.38426.63 ± 35.42132.48 ± 44.94035.31 ± 40.09021.69 ± 32.493
Day 1, 2 Hours24.74 ± 31.92512.53 ± 9.86527.49 ± 38.09132.22 ± 51.91634.58 ± 55.20934.64 ± 69.767
Day 1, 4 Hours30.94 ± 38.87915.64 ± 15.81625.43 ± 32.73328.87 ± 44.08742.23 ± 68.62332.51 ± 49.200
Week 221.26 ± 15.69321.89 ± 16.69227.56 ± 28.25931.43 ± 30.06045.48 ± 55.69723.95 ± 39.985
Week 323.43 ± 20.69424.63 ± 20.66539.28 ± 53.13735.03 ± 37.29455.91 ± 67.07221.16 ± 27.850
Week 424.81 ± 19.94023.06 ± 19.60953.45 ± 89.03126.19 ± 24.65736.17 ± 47.45119.80 ± 22.428
Week 816.59 ± 16.38329.17 ± 14.06539.62 ± 39.21025.88 ± 28.41944.44 ± 46.79928.89 ± 50.670
Week 1219.31 ± 14.22019.30 ± 19.23934.72 ± 43.35322.09 ± 24.03963.62 ± 112.99634.18 ± 44.742
Day 9515.64 ± 13.17121.97 ± 11.66932.13 ± 32.10725.58 ± 31.91361.37 ± 75.39017.86 ± 23.381
Day 9920.26 ± 16.10420.17 ± 10.38233.46 ± 42.56118.14 ± 20.26537.89 ± 41.71013.58 ± 18.308
Day 10011.60 ± 12.75017.53 ± 11.56827.61 ± 34.12619.74 ± 16.52033.18 ± 33.67516.30 ± 21.186
Day 1029.16 ± 7.80121.20 ± 18.47734.52 ± 31.00618.66 ± 22.56243.68 ± 47.51521.45 ± 28.939
Day 10417.17 ± 10.77037.43 ± 54.48746.92 ± 57.51030.71 ± 50.48980.67 ± 138.15840.43 ± 73.514
PrimaryPlasma KLK1 Concentration Pre and Post DM199 Administration

Observed KLK1 concentration throughout the treatment period.

Time frame:
Baseline through Day 104
Reported as:
Mean · ng/mL
Plasma KLK1 Concentration Pre and Post DM199 Administration
ng/mLCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort I: 2 ug/kg DM199ICohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Baseline3.0909 ± 5.013271.2133 ± 2.425873.1077 ± 4.627760.8775 ± 1.938290.7500 ± 1.392022.0558 ± 3.34727
Day 1, 2 Hours2.1146 ± 3.585651.7047 ± 2.424613.4808 ± 4.906711.4842 ± 1.797661.2551 ± 2.529523.2989 ± 3.72430
Day 1, 4 Hours2.2868 ± 3.583802.1045 ± 2.629043.7485 ± 4.673051.3269 ± 0.938461.3779 ± 2.529563.3180 ± 3.67831
Week 22.9117 ± 3.841326.2710 ± 4.028853.8417 ± 2.755414.8071 ± 3.072381.8441 ± 1.931965.7693 ± 4.49985
Week 32.2178 ± 1.337805.3430 ± 4.267203.8708 ± 3.124694.6389 ± 2.192671.6892 ± 1.679986.9004 ± 4.99114
Week 42.0375 ± 1.398955.6896 ± 4.587973.5852 ± 2.984404.2348 ± 2.950711.8121 ± 2.465817.3027 ± 4.77157
Week 81.8525 ± 0.824224.5991 ± 4.141883.7705 ± 3.583964.4250 ± 3.339911.4225 ± 1.261796.2775 ± 4.41415
Week 122.0000 ± 1.890493.2071 ± 2.515133.4816 ± 3.291903.5169 ± 2.486061.9474 ± 2.625535.9806 ± 4.90394
Day 952.2189 ± 2.137754.1067 ± 2.402333.3046 ± 2.915564.2130 ± 3.612801.9837 ± 2.717575.4063 ± 4.78979
Day 991.7450 ± 1.637762.7533 ± 2.402653.5395 ± 2.994862.9776 ± 3.348711.4749 ± 2.972545.5500 ± 4.55581
Day 1001.3625 ± 1.583272.9280 ± 2.136302.3614 ± 2.179992.4288 ± 3.316790.8899 ± 0.757724.6521 ± 4.17552
Day 1021.2020 ± 1.673471.6486 ± 1.235943.1495 ± 3.383451.8563 ± 3.143100.3166 ± 0.176134.3348 ± 4.51474
Day 1041.0423 ± 1.497160.8484 ± 0.632392.1383 ± 2.142161.4505 ± 2.911550.3158 ± 0.228052.8327 ± 3.94124
SecondaryTumor Necrosis Factor Receptor 1 (TNF-R1) Concentration in Plasma, Change From Baseline

Tumor Necrosis Factor Receptor 1 (TNF-R1) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.

Time frame:
Baseline, Weeks 4, 8, 12, and 14
Reported as:
Mean · ug/L
Tumor Necrosis Factor Receptor 1 (TNF-R1) Concentration in Plasma, Change From Baseline
ug/LCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Week 4-0.12 ± 0.274-0.02 ± 0.2910.12 ± 0.231-0.15 ± 0.284-0.01 ± 0.272-0.03 ± 0.317
Week 80.13 ± 0.3090.11 ± 0.1960.28 ± 0.344-0.10 ± 0.327-0.05 ± 0.362-0.15 ± 0.283
Week 12-0.01 ± 0.1450.07 ± 0.2340.23 ± 0.314-0.18 ± 0.249-0.02 ± 0.270-0.04 ± 0.417
Week 140.02 ± 0.2280.18 ± 0.0840.21 ± 0.397-0.12 ± 0.199-0.03 ± 0.255-0.07 ± 0.408
SecondaryC-Reactive Protein (CRP) Concentration in Plasma, Change From Baseline

C-Reactive Protein (CRP) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.

Time frame:
Baseline, Weeks 4, 8, 12, and 14
Reported as:
Mean · nmol/L
C-Reactive Protein (CRP) Concentration in Plasma, Change From Baseline
nmol/LCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Week 43.1430 ± 51.843499.0478 ± 39.933485.8731 ± 13.32043-13.5935 ± 24.1995028.5719 ± 87.84903-10.4129 ± 54.56484
Week 8-5.9524 ± 39.1817853.1439 ± 143.6597144.4452 ± 67.06411-13.0478 ± 29.24145-12.2621 ± 20.79303-16.4884 ± 71.63561
Week 12-6.6668 ± 26.73095-5.0000 ± 42.29579137.5423 ± 445.21130-6.8782 ± 17.08213-8.7076 ± 25.57443-19.1671 ± 62.96485
Week 14-7.5001 ± 33.2167716.1908 ± 45.5002340.0801 ± 123.03326-13.8096 ± 29.12155-2.9841 ± 18.5127314.7028 ± 110.90787
SecondaryMatrix Metalloproteainase-9 (MMP-9) Concentration in Plasma, Change From Baseline

Matrix Metalloproteainase-9 (MMP-9) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement. Matrix Metalloproteinase-9 (MMP-9) was measured throughout the treatment period as a biomarker of extracellular matrix remodeling, inflammation, and tissue injury. MMP-9 is a member of the matrix metalloproteinase family of enzymes that degrade components of the extracellular matrix and play a critical role in physiological and pathological processes, including wound healing, immune cell migration, vascular remodeling, fibrosis, and inflammatory responses. Elevated MMP-9 levels have been associated with various disease states, including chronic kidney disease, cardiovascular disease, inflammatory disorders, and conditions characterized by tissue damage and remodeling.

Time frame:
Baseline, Weeks 4, 8, 12, and 14
Reported as:
Mean · ug/L
Matrix Metalloproteainase-9 (MMP-9) Concentration in Plasma, Change From Baseline
ug/LCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Week 417.26 ± 108.145-0.49 ± 14.6479.29 ± 240.618-22.82 ± 81.174-60.87 ± 166.03129.80 ± 117.822
Week 810.30 ± 78.654-16.72 ± 43.999-10.17 ± 66.284-31.84 ± 95.925-34.14 ± 153.432-1.88 ± 38.444
Week 128.59 ± 72.381-47.85 ± 95.50220.43 ± 224.725-38.30 ± 106.4411.05 ± 44.66563.24 ± 165.204
Week 14-3.38 ± 65.6632.88 ± 28.374-40.60 ± 182.660-30.99 ± 98.844-35.44 ± 165.781-6.85 ± 30.198
SecondaryVascular Endothelial Growth Factor (VEGF) Concentration in Plasma, Change From Baseline

Vascular Endothelial Growth Factor (VEGF) concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.

Time frame:
Baseline, Weeks 4, 8, 12, and 14
Reported as:
Mean · ng/L
Vascular Endothelial Growth Factor (VEGF) Concentration in Plasma, Change From Baseline
ng/LCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Week 4-22.55 ± 88.842-3.41 ± 39.485-12.25 ± 80.5321.05 ± 26.077-16.92 ± 29.600-0.38 ± 20.885
Week 8-48.66 ± 76.20243.21 ± 61.846-33.77 ± 65.3513.67 ± 15.0514.45 ± 26.689-0.21 ± 23.564
Week 12-37.42 ± 75.241-21.77 ± 77.284-14.46 ± 31.225-2.36 ± 19.79315.50 ± 30.08715.98 ± 17.451
Week 14-5.28 ± 62.97225.50 ± 15.5564.43 ± 41.063-8.88 ± 17.2454.63 ± 44.3763.81 ± 13.884
SecondaryCystatin C Concentration in Plasma, Change From Baseline

Cystatin C concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement.

Time frame:
Baseline, Weeks 4, 8, 12, and 14
Reported as:
Mean · ug/L
Cystatin C Concentration in Plasma, Change From Baseline
ug/LCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Week 4-147.77 ± 661.456-82.53 ± 278.84836.59 ± 428.227-91.22 ± 422.600-142.87 ± 964.97819.86 ± 910.209
Week 8121.63 ± 916.429-1.99 ± 680.486190.72 ± 758.873125.80 ± 689.21066.74 ± 775.026-50.43 ± 654.957
Week 12-388.97 ± 754.84411.52 ± 285.072244.88 ± 470.071-136.93 ± 685.749-31.22 ± 705.663-84.49 ± 1015.488
Week 14-172.68 ± 769.966142.64 ± 715.372305.55 ± 518.9797.23 ± 674.078-59.44 ± 689.961-233.23 ± 823.811
SecondaryProstaglandin E2 Concentration in Plasma, Change From Baseline

Prostaglandin E2 concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement. Prostaglandin E2 is a biomarker of inflammatory activity, immune regulation, and physiological processes involved in vascular and renal function. PGE2 is a bioactive lipid mediator derived from arachidonic acid through the cyclooxygenase (COX) pathway and is produced by a variety of cell types in response to inflammatory stimuli, tissue injury, and other physiological signals. PGE2 plays an important role in modulating inflammation, vasodilation, blood flow regulation, immune responses, and maintenance of normal kidney function.

Time frame:
Baseline, Weeks 4, 8, 12, and 14
Reported as:
Mean · ng/L
Prostaglandin E2 Concentration in Plasma, Change From Baseline
ng/LCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Week 493.22 ± 279.780254.77 ± 767.177185.96 ± 477.878586.65 ± 1542.503-92.33 ± 515.393-196.74 ± 1148.824
Week 857.53 ± 204.382170.72 ± 712.769182.10 ± 416.398707.04 ± 1759.144-223.01 ± 881.133-185.41 ± 1060.557
Week 1239.91 ± 229.710405.02 ± 733.275402.95 ± 683.799670.32 ± 1643.506-262.08 ± 866.935-222.32 ± 1140.811
Week 14672.47 ± 1319.35665.86 ± 179.093454.15 ± 960.015596.23 ± 1403.538-51.92 ± 910.30714.18 ± 1665.939
SecondaryProstacyclin Concentration in Plasma, Change From Baseline

Prostacyclin concentration in plasma measured over the duration of the treatment period and compared to the baseline concentration measurement. Prostacyclin is a biomarker of vascular function, endothelial health, and regulation of platelet activity. Prostacyclin, also known as prostaglandin I2 (PGI2), is a biologically active lipid mediator produced primarily by vascular endothelial cells through the cyclooxygenase pathway. It plays a critical role in maintaining vascular homeostasis by promoting vasodilation, inhibiting platelet aggregation, and helping to regulate blood flow and vascular tone. Prostacyclin is also involved in modulating inflammatory responses and protecting against the development of thrombosis and vascular injury.

Time frame:
Baseline, Weeks 4, 8, 12, and 14
Reported as:
Mean · ng/L
Prostacyclin Concentration in Plasma, Change From Baseline
ng/LCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Week 4-13.08 ± 29.22015.60 ± 29.4681.99 ± 15.1306.09 ± 43.526-4.13 ± 35.4101.68 ± 33.930
Week 8-19.29 ± 23.985-5.10 ± 47.13015.48 ± 36.18111.09 ± 22.3394.93 ± 37.2796.49 ± 28.535
Week 12-25.17 ± 25.38610.20 ± 29.09526.48 ± 43.59613.25 ± 46.7812.98 ± 29.0682.53 ± 31.487
Week 142.47 ± 48.42014.60 ± 36.18521.76 ± 29.08118.63 ± 36.7472.93 ± 32.418-6.69 ± 50.053
SecondaryKidney Injury Molecule-1 (KIM-1) Concentration in Urine, Change From Baseline

Kidney Injury Molecule-1 (KIM-1) concentration in urine measured over the duration of the treatment period and compared to the baseline concentration measurement.

Time frame:
Baseline, Weeks 4, 8, 12, and 14
Reported as:
Mean · ng/L
Kidney Injury Molecule-1 (KIM-1) Concentration in Urine, Change From Baseline
ng/LCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Week 4236.01 ± 1060.149192.50 ± 689.87743.21 ± 576.908-293.90 ± 751.931-463.36 ± 1560.34011.77 ± 898.226
Week 8-215.47 ± 503.815180.34 ± 360.329309.51 ± 1503.507-345.98 ± 573.113-194.27 ± 1010.344294.28 ± 1071.373
Week 12-107.59 ± 483.736283.38 ± 286.078-92.63 ± 799.761-195.48 ± 730.647-623.04 ± 1165.895789.43 ± 1077.718
Week 14-104.48 ± 297.454-71.38 ± 342.880-177.55 ± 1045.979-87.97 ± 756.976219.30 ± 1481.125443.71 ± 1044.764
SecondaryNeutrophil Gelatinase-Associated Lipocalin (NGAL) Concentration in Urine, Change From Baseline

Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine measured over the duration of the treatment period and compared to the baseline concentration measurement.

Time frame:
Baseline, Weeks 4, 8, 12, and 14
Reported as:
Mean · ug/L
Neutrophil Gelatinase-Associated Lipocalin (NGAL) Concentration in Urine, Change From Baseline
ug/LCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Week 4-26.98 ± 43.35949.76 ± 222.701-9.48 ± 245.4842.84 ± 148.485-33.65 ± 66.059-21.71 ± 97.002
Week 8-21.93 ± 40.2891.29 ± 97.210-34.02 ± 225.233-51.84 ± 95.887-34.30 ± 124.384-38.94 ± 68.383
Week 1210.44 ± 90.799-9.56 ± 136.828-37.27 ± 253.220-85.75 ± 125.603-53.73 ± 120.15434.64 ± 194.382
Week 145.48 ± 71.887-66.53 ± 105.157-60.78 ± 226.990-50.24 ± 121.014-55.81 ± 94.272-48.21 ± 107.276

Adverse events

Collected over From first dose on Day 1 through Day 104. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort I: 2 ug/kg DM1990/11 (0%)2/11 (18.2%)7/11 (63.6%)
Cohort I: 5 ug/kg DM1991/12 (8.3%)1/12 (8.3%)10/12 (83.3%)
Cohort II: 2 ug/kg DM1990/13 (0%)2/13 (15.4%)7/13 (53.8%)
Cohort II: 5 ug/kg DM1990/12 (0%)0/12 (0%)8/12 (66.7%)
Cohort III: 2 ug/kg DM1990/17 (0%)2/17 (11.8%)6/17 (35.3%)
Cohort III: 5 ug/kg DM1990/17 (0%)4/17 (23.5%)10/17 (58.8%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Acute kidney injuryRenal and urinary disorders1/110/120/130/121/172/17
Acute myocardial infarctionCardiac disorders1/110/120/130/120/171/17
Hypertensive urgencyVascular disorders1/110/120/130/120/170/17
HypotensionVascular disorders1/110/120/130/120/170/17
AngioedemaSkin and subcutaneous tissue disorders1/110/120/130/120/170/17
DeathGeneral disorders0/111/120/130/120/170/17
Atrial fibrillationCardiac disorders0/110/121/130/120/171/17
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/110/121/130/120/171/17
COVID-19 pneumoniaInfections and infestations0/110/121/130/120/170/17
Cardiac failure congestiveCardiac disorders0/110/120/130/121/170/17
Most frequent other events
Showing 10 of 109
Most frequent other events
EventCohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199
Injection site painGeneral disorders1/113/122/136/123/172/17
Injection site erythemaGeneral disorders1/111/122/135/122/173/17
HypertensionVascular disorders4/111/123/131/122/173/17
Injection site swellingGeneral disorders0/112/121/132/121/172/17
Injection site bruisingGeneral disorders0/110/121/132/121/170/17
Injection site pruritusGeneral disorders1/111/122/131/120/170/17
SinusitisInfections and infestations0/110/122/130/120/170/17
HypokalaemiaMetabolism and nutrition disorders0/110/122/130/120/171/17
PneumoniaInfections and infestations0/110/120/130/121/172/17
HyperkalaemiaMetabolism and nutrition disorders0/110/120/130/122/172/17

Baseline characteristics

\[1\] Safety Population: All participants who have received any amount of study drug. Participants are summarized according to the dose received. Demographic, baseline characteristics, urinary concentration of KLK1, and safety and tolerability analyses were conducted using the Safety Population. \[2\] Participants 07-310 and 14-101 were randomized but not treated (and excluded from the Safety Population) because they were lost to follow-up and had a Covid infection respectively.

Age, Continuous
Age, Continuous(Years)Cohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199Total
Mean51.5 ± 12.6660.0 ± 13.7951.2 ± 12.1946.5 ± 9.8163.2 ± 9.3368.4 ± 7.1857.9 ± 13.03
Sex: Female, Male
Sex: Female, Male(Participants)Cohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199Total
Female28538632
Male948991150
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199Total
White00111011739
Black or African American1112104836
Asian0011125
Other0001102
Estimated Glomerular Filtration Rate (eGFR)
Estimated Glomerular Filtration Rate (eGFR)(mL/min/1.73m^2)Cohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199Total
Mean50.04 ± 17.59350.50 ± 22.58446.55 ± 17.27549.95 ± 19.62949.19 ± 16.85041.95 ± 13.60947.69 ± 17.520
Urine Albumin Creatinine Ratio (UACR)
Urine Albumin Creatinine Ratio (UACR)(g/kg)Cohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199Total
Mean805.66 ± 968.520656.57 ± 761.4421001.35 ± 857.728741.20 ± 442.4231051.47 ± 893.2291371.56 ± 1513.248971.77 ± 1003.196
Systolic Blood Pressure
Systolic Blood Pressure(mmHg)Cohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199Total
Mean148.0 ± 30.51143.2 ± 18.47131.0 ± 11.24126.3 ± 13.39139.0 ± 11.73144.8 ± 14.07138.9 ± 18.04
Diastolic Blood Pressure
Diastolic Blood Pressure(mmHg)Cohort I: 2 ug/kg DM199Cohort I: 5 ug/kg DM199Cohort II: 2 ug/kg DM199Cohort II: 5 ug/kg DM199Cohort III: 2 ug/kg DM199Cohort III: 5 ug/kg DM199Total
Mean92.4 ± 16.5785.7 ± 9.6683.5 ± 8.2781.2 ± 11.7880.3 ± 6.1378.5 ± 6.3283.0 ± 10.50
08

Study locations

14 sites
  • Aventiv Research
    Mesa, Arizona 85210, United States
  • Amicis Research Center
    Granada Hills, California 91344, United States
  • Amicis Reserch Center
    Granada Hills, California 91344, United States
  • IMD Clinical Trials Inc
    Los Angeles, California 90033, United States
  • Innovative Healthcare Institute
    Coral Springs, Florida 33067, United States
  • Elixia at Florida Kidney Physicians-SE
    Fort Lauderdale, Florida 33308, United States
  • Pines Clinical Research-Hollywood
    Hollywood, Florida 33024, United States
  • Elixia at Florida Kidney Physicians
    Temple Terrace, Florida 33637, United States
  • Boise Kidney & Hypertension Institute
    Meridian, Idaho 83642, United States
  • Research by Design LLC
    Chicago, Illinois 60643, United States
  • New Orleans Center for Clinical Research, an AMR Company
    New Orleans, Louisiana 70119, United States
  • Elixia At Clinical Renal Associates
    Upland, Pennsylvania 19013, United States
  • Nephrotex Research Group, LLC
    Dallas, Texas 75231, United States
  • RDRI
    DeSoto, Texas 75115, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Mar 2022, 26 months.

Results were first posted in Nov 2026, 4 years 7 months after primary completion.

Of 41 phase 2 interventional studies under Kidney Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 26 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2019
First posted
Oct 11, 2019
StartActual
Dec 17, 2019
Primary completionActual
Mar 16, 2022
CompletionActual
Mar 16, 2022
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 10, 2026
Sites
3 sites added, 3 sites removed
Show 3 added (3 United States)
  • Amicis Research Center · Granada Hills, United States
  • Amicis Reserch Center · Granada Hills, United States
  • Elixia At Clinical Renal Associates · Upland, United States
Show 3 removed
  • Amcis Research Center · Granada Hills, United States
  • Amicis Reserch Center · Northridge, United States
  • Elixia At Clincal Renal Associates · Upland, United States
Nov 10, 2026
Enrollment
79→84
Nov 10, 2026
Primary outcomes
1 edited, 6 added, 3 removed
What changed in the outcomes
  • EditedChange in urine albuminUrine Albumin to creatinine ratioCreatinine Ratio (UACR), Change From BaselineTime frame: 12 weeks → Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, and 16
  • AddedSafety as Assessed by Incidence, Severity and Causality of AEsTime frame: From initial dose (Day 1) through Day 104
  • AddedEstimated Glomerular Filtration Rate (eGFR), Change From BaselineTime frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, and 16
  • AddedSystolic Blood Pressure, Change From BaselineTime frame: Baseline, Day 4 through Day 95
  • AddedDiastolic Blood Pressure, Change From BaselineTime frame: Baseline, Day 4 through Day 95
  • AddedUrine KLK1 Concentration Pre and Post DM199 AdministrationTime frame: Baseline through Day 104
  • AddedPlasma KLK1 Concentration Pre and Post DM199 AdministrationTime frame: Baseline through Day 104
  • RemovedIncidence of treatment emergent adverse eventsTime frame: 12 weeks
  • RemovedChange in renal functionTime frame: 12 weeks
  • RemovedPlasma measurements of DM199Time frame: 12 weeks
Nov 10, 2026
Documents
Secondary outcomes
7 edited, 2 added
What changed in the outcomes
  • EditedTumor necrosis factor receptorNecrosis Factor Receptor 1 (TNF -R1) concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
  • EditedC-reactive proteinReactive Protein (CRP) concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
  • EditedMatrix metalloproteainaseMetalloproteainase-9 (MMP-9) concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
  • EditedVascular endothelial growth factorEndothelial Growth Factor (VEGF) concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
  • EditedCystatin C concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
  • EditedProstaglandin E2 concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
  • EditedProstacyclin concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
  • AddedKidney Injury Molecule-1 (KIM-1) Concentration in Urine, Change From BaselineTime frame: Baseline, Weeks 4, 8, 12, and 14
  • AddedNeutrophil Gelatinase-Associated Lipocalin (NGAL) Concentration in Urine, Change From BaselineTime frame: Baseline, Weeks 4, 8, 12, and 14
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Results posted
    3 sites added, 3 sites removed
    Show 3 added (3 United States)
    • Amicis Research Center · Granada Hills, United States
    • Amicis Reserch Center · Granada Hills, United States
    • Elixia At Clinical Renal Associates · Upland, United States
    Show 3 removed
    • Amcis Research Center · Granada Hills, United States
    • Amicis Reserch Center · Northridge, United States
    • Elixia At Clincal Renal Associates · Upland, United States
    Enrollment 79→84
    Primary outcomes 1 edited, 6 added, 3 removed
    What changed in the outcomes
    • EditedChange in urine albuminUrine Albumin to creatinine ratioCreatinine Ratio (UACR), Change From BaselineTime frame: 12 weeks → Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, and 16
    • AddedSafety as Assessed by Incidence, Severity and Causality of AEsTime frame: From initial dose (Day 1) through Day 104
    • AddedEstimated Glomerular Filtration Rate (eGFR), Change From BaselineTime frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, and 16
    • AddedSystolic Blood Pressure, Change From BaselineTime frame: Baseline, Day 4 through Day 95
    • AddedDiastolic Blood Pressure, Change From BaselineTime frame: Baseline, Day 4 through Day 95
    • AddedUrine KLK1 Concentration Pre and Post DM199 AdministrationTime frame: Baseline through Day 104
    • AddedPlasma KLK1 Concentration Pre and Post DM199 AdministrationTime frame: Baseline through Day 104
    • RemovedIncidence of treatment emergent adverse eventsTime frame: 12 weeks
    • RemovedChange in renal functionTime frame: 12 weeks
    • RemovedPlasma measurements of DM199Time frame: 12 weeks
    Secondary outcomes 7 edited, 2 added
    What changed in the outcomes
    • EditedTumor necrosis factor receptorNecrosis Factor Receptor 1 (TNF -R1) concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
    • EditedC-reactive proteinReactive Protein (CRP) concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
    • EditedMatrix metalloproteainaseMetalloproteainase-9 (MMP-9) concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
    • EditedVascular endothelial growth factorEndothelial Growth Factor (VEGF) concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
    • EditedCystatin C concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
    • EditedProstaglandin E2 concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
    • EditedProstacyclin concentrationConcentration in plasmaPlasma, change from baselineChange From BaselineTime frame: 12 weeks → Baseline, Weeks 4, 8, 12, and 14
    • AddedKidney Injury Molecule-1 (KIM-1) Concentration in Urine, Change From BaselineTime frame: Baseline, Weeks 4, 8, 12, and 14
    • AddedNeutrophil Gelatinase-Associated Lipocalin (NGAL) Concentration in Urine, Change From BaselineTime frame: Baseline, Weeks 4, 8, 12, and 14
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04123613
Lead sponsor
DiaMedica Therapeutics Inc
Responsible party
Sponsor
First posted
Oct 11, 2019
Start date
Dec 17, 2019
Primary completion
Mar 16, 2022
Completion
Mar 16, 2022
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

Kirsten Gruis, MD
study director · DiaMedica Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DM199

Start the discussion